» Articles » PMID: 24909251

Leptin -2548g/a Gene Polymorphism in Association with Antipsychotic-induced Weight Gain: a Meta-analysis Study

Overview
Journal Psychiatr Danub
Specialty Psychiatry
Date 2014 Jun 10
PMID 24909251
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The leptin -2548G/A (rs7799039) gene polymorphism has been implicated in susceptibility to antipsychotic-induced weight gain (AIWG), but study results are still controversial. The present meta-analysis was performed to investigate the relationship between the leptin -2548G/A gene polymorphism and AIWG.

Methods: Electronic databases were searched for eligible articles in English and Chinese and seven separate studies on the association of the leptin -2548G/A gene polymorphism with AIWG were analyzed.

Results: The meta-analysis involved 451 AIWG patients and 568 controls. The pooled odds ratio (OR) and their corresponding 95% confidence interval (CI) were calculated by a fixed or random effect. Overall, our meta-analysis suggests that the leptin -2548G/A gene polymorphism was not significantly associated with AIWG risk under various genetic models. But, in the subgroup analysis by ethnicity, significant association was found between leptin -2548A allele and the AIWG risk in Asian populations under additive, dominant, recessive, and homozygote genetic model. On the contrary, in European populations, the -2548A allele seemed to decrease the risk of AIWG when compared with the -2548G allele under various genetic models, even though they were not statistically significant.

Conclusion: Our meta-analysis suggests that the correlation between leptin -2548G/A gene polymorphism and AIWG risk has significant racial differences.

Citing Articles

LEP rs7799039 and LEPR rs1137101 gene variants are not associated with clinical features in patients with metabolic syndrome in the Turkish population.

Jabbarli M, Senkal N, Tuncel F, Oyaci Y, Guzel Dirim M, Kose M Lab Med. 2024; 56(1):37-43.

PMID: 39136228 PMC: 11700887. DOI: 10.1093/labmed/lmae061.


The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Teng Y, Sandhu A, Liemburg E, Naderi E, Alizadeh B J Pers Med. 2023; 13(3).

PMID: 36983653 PMC: 10052041. DOI: 10.3390/jpm13030471.


Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.

Guan X, Xu J, Xiu M, Li X, Liu H, Wu F CNS Neurosci Ther. 2022; 28(10):1539-1546.

PMID: 35769008 PMC: 9437236. DOI: 10.1111/cns.13895.


The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Libowitz M, Nurmi E Front Psychiatry. 2021; 12:623681.

PMID: 33776816 PMC: 7994286. DOI: 10.3389/fpsyt.2021.623681.


C677T Polymorphism in the Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia.

Liao J, Wang N, Ma M, Lu T, Yan H, Yue W Front Psychiatry. 2020; 11:617.

PMID: 32714219 PMC: 7343847. DOI: 10.3389/fpsyt.2020.00617.